505 related articles for article (PubMed ID: 30885458)
1. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
[TBL] [Abstract][Full Text] [Related]
2. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
3. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
4. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.
Nam RK; Cheung P; Herschorn S; Saskin R; Su J; Klotz LH; Chang M; Kulkarni GS; Lee Y; Kodama RT; Narod SA
Lancet Oncol; 2014 Feb; 15(2):223-31. PubMed ID: 24440474
[TBL] [Abstract][Full Text] [Related]
5. Is there an increased risk of second primaries following prostate irradiation?
Movsas B; Hanlon AL; Pinover W; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):251-5. PubMed ID: 9607337
[TBL] [Abstract][Full Text] [Related]
6. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract][Full Text] [Related]
10. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
11. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
12. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
13. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.
Brenner DJ; Curtis RE; Hall EJ; Ron E
Cancer; 2000 Jan; 88(2):398-406. PubMed ID: 10640974
[TBL] [Abstract][Full Text] [Related]
14. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study.
Wolf A; Naylor K; Tam M; Habibi A; Novotny J; Liščák R; Martinez-Moreno N; Martinez-Alvarez R; Sisterson N; Golfinos JG; Silverman J; Kano H; Sheehan J; Lunsford LD; Kondziolka D
Lancet Oncol; 2019 Jan; 20(1):159-164. PubMed ID: 30473468
[TBL] [Abstract][Full Text] [Related]
15. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
16. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.
Berrington de Gonzalez A; Curtis RE; Kry SF; Gilbert E; Lamart S; Berg CD; Stovall M; Ron E
Lancet Oncol; 2011 Apr; 12(4):353-60. PubMed ID: 21454129
[TBL] [Abstract][Full Text] [Related]
17. [The risk of subsequent primary cancer after radiotherapy of localised prostate cancer with carbon ions may be reduced compared to treatment with photons].
Kraus KM; Combs SE
Strahlenther Onkol; 2019 Nov; 195(11):1033-1035. PubMed ID: 31420708
[No Abstract] [Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
19. Incidence of second malignancies among patients treated with proton versus photon radiation.
Chung CS; Yock TI; Nelson K; Xu Y; Keating NL; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):46-52. PubMed ID: 23778197
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer.
Bagshaw HP; Arnow KD; Trickey AW; Leppert JT; Wren SM; Morris AM
JAMA Netw Open; 2022 Jul; 5(7):e2223025. PubMed ID: 35900763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
